Business
Director Share Purchase
Director Share Purchase.
About this update from Solvonis Therapeutics Plc
[{"type":"text","content":"\n\n \n16 May 2023\n \nGraft Polymer (UK) Plc\n(\"Graft Polymer\", the \"Company\", and together with its subsidiaries, the \"Group\")\n \nDirector Share Purchase\n \n \nGraft Polymer (UK) Plc, a business focused on the development and commercial production of modified polymer solutions including additives, alloys, synthesis, and drug delivery systems, announces that on 15 May 2023, Alex Brooks, Non-Executive Director of Graft Polymer, acquired 56,399 Ordinary Shares at an average price of 4.6 pence per Ordinary Share. Following this acquisition of shares, Alex Brooks has a total beneficial interest in 475,004 Ordinary Shares, representing approximately 0.46% of the total issued share capital of the Company.\n \n \n \n -Ends-\n \nAuthorised for release by the board of directors, for further information please contact:\n \n\n\n\nGraft Polymer (UK) Plc (via St Brides Partners)\n\n\nSt Brides Partners (Public Relations)\n\n\n\n\nRoby Zomer, Non Executive Chairman\nYifat Steuer, CFO and Executive Director\nhttps://www.graftpolymer.com\n\n\nCatherine Leftley\nAna Ribeiro\nMax Bennett\[email protected]\n\n\n\n\n\n\n\n\n\n\n\n\nTurner Pope Investments (Broker)\n\n\n \n\n\n\n\nJames Pope\nAndy Thacker\n+44 20 3657 0050\n\n\n\n\n\n\n \n \nAbout Graft Polymer\n \nGraft Polymer is a London Stock Exchange listed company (GPL.L) with a cutting-edge, cash-flow positive, research and development (R&D) and manufacturing facility based in Slovenia which has already introduced more than 50 products to the market. The core business of the Group comprises polymer modification and drug delivery system developments. The Group has developed a proprietary set of polymer modification technologies which uses recycled raw materials and a closed loop system to reduce waste. Graft Polymer's technology can improve existing products and processing methodologies by enhancing performance, simplifying manufacturing, reducing material consumption, widening the choice of feedstocks, and reducing costs.\nGraft Polymer has two divisions: the first division focusses on polymer modification; the second is GraftBio which develops IP for Bio/Pharma applications (including a drug delivery system to support and provide solutions to the market, which had been heavily imp...